Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Cervarix™ or control [Al(OH)3] has been administered in the primary study NCT00294047.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Occurrence of positive oncogenic HPV DNA results in cervical samples by HPV DNA testing
Throughout the study (month 12 to month 48 post last study visit study NCT00294047)
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
Peru: Instituto Nacional de Salud
113617
NCT01190176
September 2011
April 2018
Name | Location |
---|---|
GSK Investigational Site | Bettendorf, Iowa 52722 |
GSK Investigational Site | Kansas City, Kansas 66160 |
GSK Investigational Site | Seattle, Washington 98133 |